Welcome to our dedicated page for Orchestra BioMed Holdings SEC filings (Ticker: OBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Orchestra BioMed Holdings, Inc. filings document the governance, financing and material agreements of a biomedical company developing AVIM Therapy and Virtue SAB through strategic medical-device partnerships. Current reports describe revenue participation rights, strategic financing, distribution and right-of-first-refusal arrangements, underwritten common stock and pre-funded warrant offerings, investor presentations, and other business updates.
Proxy materials cover board elections, auditor ratification, executive compensation votes, equity and employee stock purchase plans, and related annual-meeting governance. The filing record also includes compensatory-arrangement disclosures for executive bonus plans, registration-statement references, exhibit filings and capital-structure disclosure tied to its cardiovascular product candidates.
RTW Investments and affiliated funds updated their ownership report on Orchestra BioMed Holdings after exercising pre-funded warrants. On April 27, 2026, the RTW funds exercised pre-funded warrants for 1,250,032 shares at $0.0001 per share on a cashless basis, leading to 1,250,000 new common shares being issued and 32 shares withheld to cover the exercise price.
Following these transactions and including certain additional warrants exercisable within 60 days, RTW Investments and Dr. Roderick Wong are reported as beneficial owners of 11,942,394 shares of common stock, representing 19.2% of Orchestra BioMed’s outstanding common stock as calculated in the filing.
Orchestra BioMed Holdings, Inc. reported that affiliated RTW funds exercised pre-funded warrants to acquire 1,250,032 shares of common stock at $0.0001 per share on a cashless basis. The issuer withheld 32 shares to satisfy the exercise price and issued 1,250,000 shares to the RTW funds.
After the transactions, the reporting parties indirectly held 9,556,095 shares of common stock and 2,386,331 pre-funded warrants. The RTW funds and their attribution parties are limited to beneficial ownership of no more than 19.99% of outstanding common stock following any exercise, and the reporting persons disclaim beneficial ownership except to the extent of their pecuniary interest.
Orchestra BioMed Holdings, Inc. is asking stockholders to vote at its 2026 virtual annual meeting on June 23, 2026. The agenda includes electing three Class III directors, ratifying Ernst & Young LLP as auditor, and advisory votes on executive pay and pay frequency.
The company also seeks approval of a 2026 Employee Stock Purchase Plan authorizing up to 750,000 shares, which it estimates represents about 1.25% overhang based on 59,880,715 shares outstanding as of April 28, 2026. The meeting will be held online via live audio webcast, with full voting and Q&A participation rights.
Orchestra BioMed Holdings director and officer Darren Sherman reported a tax-related share disposition linked to restricted stock units. On the vesting of RSUs, the company withheld 33,317 shares of common stock at an effective price of $4.57 per share to cover tax obligations. According to the filing, no shares were sold in the market in connection with this event. After this withholding, Sherman directly holds 1,204,252 shares of Orchestra BioMed common stock.
Orchestra BioMed Holdings, Inc. insider Joshua Aiello, the Principal Accounting Officer, reported a small share disposition tied to taxes, not a market trade. The company withheld 241 shares of Common Stock at $4.57 per share to cover tax obligations from restricted stock unit vesting. After this withholding, Aiello directly holds 18,644 shares of Common Stock.
Orchestra BioMed Holdings director and officer David P. Hochman reported a tax-related share disposition tied to restricted stock units. On the reported date, 32,438 shares of Common Stock at $4.57 per share were withheld by the company to satisfy RSU tax obligations, and no shares were sold in the market.
After this withholding, Hochman directly owns 1,054,029 shares of Common Stock. He also reports additional indirect holdings through several trusts, including 439,482 shares held by the DPH 2008 Trust and smaller positions in other family trusts.
Orchestra BioMed Holdings director and officer David P. Hochman bought 10,000 shares of Common Stock in an open-market purchase at a weighted average price of $4.29 per share. After this transaction, he directly owns 1,086,467 shares, with additional indirect holdings reported through several family trusts.
Orchestra BioMed Holdings is a biomedical innovation company developing device-based therapies for hypertension and artery disease through risk‑sharing partnerships. Its lead candidates are AVIM Therapy, a pacemaker‑delivered bioelectronic treatment for uncontrolled hypertension, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for coronary and peripheral artery disease.
AVIM Therapy is being co-developed with Medtronic under an exclusive global collaboration for hypertensive pacemaker patients. A pivotal BACKBEAT study is underway, targeting up to 500 patients, with enrollment completion currently planned for mid‑2026. AVIM Therapy has U.S. FDA Breakthrough Device Designation and IDE approval, and prior pilot studies showed statistically significant blood pressure reductions in pacemaker‑indicated patients.
Virtue SAB, which uses a microporous balloon to deliver an extended‑release sirolimus formulation without a permanent implant, is in a U.S. IDE pivotal Virtue Trial, expected to enroll about 740 patients with completion of enrollment planned for mid‑2027. Terumo holds a right of first refusal on coronary rights and has made multiple cash and equity investments. Ligand Pharmaceuticals has purchased a revenue participation right on future AVIM and Virtue SAB revenues for $35 million and also invested in equity. The company highlights large potential addressable markets in cardiac rhythm management and interventional cardiology.
Medtronic plc and Covidien Group S. reported shared beneficial ownership of 10,078,625 shares of Orchestra BioMed Holdings, Inc. common stock, representing 17.8%. The calculation is based on 56,464,731 shares outstanding as of November 6, 2025.
The filing is an Amendment No. 3 to a Schedule 13G/A and is signed by authorized representatives with a joint filing agreement in place.